abciximab

Home
Ligands
abciximab

GtoPdb Ligand ID: 6584

Synonyms: 7E3 antibody | antiGPIIBIIIa | C7E3 | ReoPro®

abciximab is an approved drug (FDA (1994))

Comment: Abciximab is a chimeric human-murine monoclonal antibody Fab (fragment antigen binding) fragment designed to target glycoprotein IIb/IIIa receptor, a key mediator of platelet aggregation and clot formation [2]. The invention of abciximab is covered by patent US5976532 [1], where its originating antibody is coded c7E3.

View more information in the IUPHAR Pharmacology Education Project: abciximab

References
1. Coller BS, Knight DM. (1999) Method of antithrombotic therapy using anti-GPIIb/IIIa antibodies or fragments thereof, including c7E3. Patent number: US5976532. Assignee: Centocor, Inc.. Priority date: 18/05/1988. Publication date: 02/11/1999.
2. Faulds D, Sorkin EM. (1994) Abciximab (c7E3 Fab). A review of its pharmacology and therapeutic potential in ischaemic heart disease. Drugs, 48 (4): 583-98. [PMID:7528131]

References

1. Coller BS, Knight DM. (1999)
Method of antithrombotic therapy using anti-GPIIb/IIIa antibodies or fragments thereof, including c7E3.
Patent number: US5976532. Assignee: Centocor, Inc.. Priority date: 18/05/1988. Publication date: 02/11/1999.

2. Faulds D, Sorkin EM. (1994)
Abciximab (c7E3 Fab). A review of its pharmacology and therapeutic potential in ischaemic heart disease.
Drugs, 48 (4): 583-98. [PMID:7528131]